H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) today and set a price target of $23.00. Yi Chen has given his Buy rating due to a ...

Bausch Health Companies ( (BHC)) has realeased its Q3 earnings. Here is a breakdown of the information Bausch Health Companies presented to its investors. Bausch Health Companies Inc., a ...

“I’m optimistic,” Bausch + Lomb CEO Brent Saunders told STAT. Zach Weinberg, CEO of Curie.Bio, said that while Trump’s policies on health care have been known to shift, “R.F.K. is scary ...

Bausch + Lomb shares surged Monday following reports Blackstone and TPG are considering teaming up to buy the eyecare company. A bid from Blackstone and TPG could reportedly value the company ...

Bausch Health turned down recent debt-restructuring proposals from bondholders as it explores a sale of its Bausch + Lomb vision care subsidiary that could bring in billions of dollars to pay ...

Bausch & Lomb (NYSE:BLCO) jumped 7.5% on a report that private equity firms TPG (TPG) and Blackstone (BX) are working on a joint bid for the eyecare company. Several other PE shops that have been ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

It isn't known whether Bausch + Lomb and/or Goldman is in contact with either Blackstone or TPG. According to the FT, several private equity funds mulling offers have dropped out of the race.